Legal & General Group
SNNA

Legal & General Group’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Legal & General Group’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,188
Closed -$2K – 3475
2019
Q2 		$2K Hold
2,188
– – ﹤0.01% 3483
2019
Q1 		$5K Hold
2,188
– – ﹤0.01% 3317
2018
Q4 		$5K Hold
2,188
– – ﹤0.01% 3346
2018
Q3 		$32K Hold
2,188
– – ﹤0.01% 3003
2018
Q2 		$33K Sell
2,188
-464
-17% -$7.88K ﹤0.01% 2979
2018
Q1 		$50K Buy
2,652
+1,552
+141% +$27.1K ﹤0.01% 2758
2017
Q4 		$20K Buy
1,100
+449
+69% +$9.5K ﹤0.01% 3149
2017
Q3 		$14K Buy
+651
New +$14.3K ﹤0.01% 3246

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Legal & General Group's SNNA Position: Q3 2019 in Review

Legal & General Group sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2019, closing a stake of 2,188 shares — an estimated $2K sold.

Legal & General Group first reported a position in SNNA in Q3 2017 and held it in 8 quarters. The position peaked at $50K in Q1 2018. 23 funds tracked by Wall St. Rank hold SNNA as of Q3 2019.

  • Legal & General Group reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Legal & General Group sold 2,188 Sienna Biopharmaceuticals, Inc. shares in Q3 2019, an estimated $2K.
  • Legal & General Group first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 8 quarters.
  • Legal & General Group's Sienna Biopharmaceuticals, Inc. position peaked at $50K in Q1 2018.
  • 23 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2019.

Based on Legal & General Group's 13F filing for Q3 2019, filed 13 Nov 2019.